|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
These data show that OPG can act as a soluble factor in the regulation of bone mass and imply a utility for OPG in the treatment of osteoporosis associated with increased osteoclast activity.
|
9108485 |
1997 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.
|
10499489 |
1999 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.
|
10952716 |
2000 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that a single adenoviral gene transfer can produce persistent high-level OPG expression and shows that gene therapy to provide sustained delivery of OPG may prove useful in treating osteoporosis.
|
11237676 |
2001 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Conversely, ablation of the OPG gene causes severe osteoporosis in mice.
|
11375772 |
2001 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
In fact, OPG could represent the long sought-after molecular link between arterial calcification and bone resorption, which underlies the clinical coincidence of vascular disease and osteoporosis, which are most prevalent in postmenopausal women and elderly people.
|
11950689 |
2002 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis.
|
12181640 |
2002 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although, no evidence of significant linkage between OPG and osteoporosis was found, a possible association of one SNP, located in the promoter region of the gene, was identified.
|
12181640 |
2002 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease.
|
12213849 |
2002 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
These findings implicate a role for OPG in the development of osteoporosis.
|
12213850 |
2002 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
LHGDN |
Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.
|
12584041 |
2003 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recently, OPG gene polymorphisms have been associated with osteoporosis and early predictors of cardiovascular disease.
|
15292302 |
2004 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.
|
15564564 |
2004 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of our work was to find polymorphisms in the OPG gene and to investigate their possible contribution to the genetic susceptibility to osteoporosis by testing for their association with bone mineral density (BMD).
|
15978970 |
2005 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, recombinant OPG may be an attractive drug in the treatment of chronic bone resorptive diseases such as osteoporosis.
|
16169783 |
2005 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, three single nucleotide polymorphisms (SNPs) within the TNFRSF11B gene were studied for association with an increased risk of osteoporosis in postmenopausal Maltese women (n=126).
|
16343827 |
2006 |
|
Osteoporosis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
OPG levels probably do not predict BMD in Gaucher disease and hence are not indicative of osteoporosis in Gaucher disease.
|
16512834 |
2006 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Estrogens also play a role in both CVD and OP through their effects on cytokines, such as IL-1, IL-6 and TNF-alpha and osteoprotegerin (OPG).
|
16550727 |
2005 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
OPG has been proposed as a link molecule between osteoporosis and arterial calcification, but the relationship between the OPG gene and the cardiovascular system in human populations is unclear.
|
16712673 |
2006 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women.
|
16949901 |
2007 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The use of the genotyping in single tube through allele-specific PCR and melting curves has led us to the accurate genotype of three polymorphisms of vdr (cdx-2), osteoprotegerin (A-163G) and ppar-gamma (C-681G) genes in 225 postmenopausal women to be associated to osteoporosis.
|
16999948 |
2007 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
|
17667143 |
2007 |
|
Osteoporosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Osteoprotegerin (OPG, TNFRSF11B) and interleukin-6 (IL-6, IL6) are putative target genes for estrogen signaling and have been implicated in both cardiovascular diseases and osteoporosis.
|
17878722 |
2007 |
|
Osteoporosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Three SNPs near the TNFRSF11B gene were associated with decreased bone mineral density (top SNP, rs4355801: p=7.6x10(-10) for lumbar spine and p=3.3x10(-8) for femoral neck) and increased risk of osteoporosis (OR 1.2, 95% CI 1.01-1.42, p=0.038).
|
18455228 |
2008 |